153 related articles for article (PubMed ID: 34282791)
61. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
[TBL] [Abstract][Full Text] [Related]
62. Somatic Copy Number Alteration in Circulating Tumor DNA for Monitoring of Pediatric Patients with Cancer.
Ruas JS; Silva FLT; Euzébio MF; Biazon TO; Daiggi CMM; Nava D; Franco MT; Cardinalli IA; Cassone AE; Pereira LH; Seidinger AL; Maschietto M; Jotta PY
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189699
[TBL] [Abstract][Full Text] [Related]
63. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
64. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
65. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
[TBL] [Abstract][Full Text] [Related]
66. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
67. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
68. Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline
Djos A; Treis D; Fransson S; Gordon Murkes L; Wessman S; Ásmundsson J; Markström A; Kogner P; Martinsson T
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140661
[TBL] [Abstract][Full Text] [Related]
69. 5'
Akhavanfard S; Nohr E; AlNajjar M; Haughn M; Hashimoto S; Deeg C; Pfau R; Brundler MA; Reshmi SC
Case Rep Oncol; 2021; 14(1):585-591. PubMed ID: 33976638
[TBL] [Abstract][Full Text] [Related]
70. Copy number alteration analysis for neuroblastoma using droplet digital polymerase chain reaction.
Ishii Y; Sato-Otsubo A; Takita J; Morio T; Takagi M
Pediatr Int; 2021 Oct; 63(10):1192-1197. PubMed ID: 33462952
[TBL] [Abstract][Full Text] [Related]
71. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
[TBL] [Abstract][Full Text] [Related]
72. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
Siravegna G; Sartore-Bianchi A; Mussolin B; Cassingena A; Amatu A; Novara L; Buscarino M; Corti G; Crisafulli G; Bartolini A; Tosi F; Erlander M; Di Nicolantonio F; Siena S; Bardelli A
Ann Oncol; 2017 Jun; 28(6):1302-1308. PubMed ID: 28368455
[TBL] [Abstract][Full Text] [Related]
73. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
[TBL] [Abstract][Full Text] [Related]
74. Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.
Beinse G; Borghese B; Métairie M; Just PA; Poulet G; Garinet S; Parfait B; Didelot A; Bourreau C; Agueeff N; Lavollé A; Terris B; Chapron C; Goldwasser F; Leroy K; Blons H; Laurent-Puig P; Taly V; Alexandre J
Clin Chem; 2022 Jun; 68(6):782-793. PubMed ID: 35323926
[TBL] [Abstract][Full Text] [Related]
75. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
76. Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors.
van Zogchel LMJ; Lak NSM; Verhagen OJHM; Tissoudali A; Gussmalla Nuru M; Gelineau NU; Zappeij-Kannengieter L; Javadi A; Zijtregtop EAM; Merks JHM; van den Heuvel-Eibrink M; Schouten-van Meeteren AYN; Stutterheim J; van der Schoot CE; Tytgat GAM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820594
[TBL] [Abstract][Full Text] [Related]
77. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
[TBL] [Abstract][Full Text] [Related]
78. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
79. Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.
van Zogchel LMJ; Lak NSM; Gelineau NU; Sergeeva I; Stelloo E; Swennenhuis J; Feitsma H; van Min M; Splinter E; Bleijs M; Groot Koerkamp M; Breunis W; Meister MT; Kholossy WH; Holstege FCP; Molenaar JJ; de Leng WWJ; Stutterheim J; van der Schoot CE; Tytgat GAM
Front Oncol; 2023; 13():1124737. PubMed ID: 37152023
[TBL] [Abstract][Full Text] [Related]
80. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
